EPF acknowledgement of Financial Support 2011

EPF wishes to thank the following sponsors for their support in the form of unrestricted grants to EPF'S
operational programme 2011 :
% of total income
AMGEN € 25,000.00 3.2%
AztraZeneca (1) € 50,000.00 6.3%
Baxter € 10,000.00 1.3%
CSL Behring € 10,000.00 1.3%
GILEAD (2) € 15,000.00 1.9%
GSK (3) € 41,932.89 5.3%
Janssen Pharmaceutica € 10,000.00 1.3%
Microsoft  € 20,000.00 2.5%
MSD € 30,000.00 3.8%
Novartis € 50,000.00 6.3%
Pfizer € 50,000.00 6.3%
Philips (4) € 20,000.00 2.5%
Phrma € 40,000.00 5.1%
Sanofi Aventis € 25,000.00 3.2%
Sanofi Pasteur MSD € 20,000.00 2.5%
Les Laboratoires Servier € 10,000.00 1.3%
Shire € 5,000.00 0.6%
(1) 2011 contribution received in 2012
(2) A contribution of € 45,000 was received from GILEAD in 2011 of which € 30,000 related to 2010 and € 15,000 to 2011
(3) GSK gave honoraria of €1000 and travel of €932,39 to support the attendance of EPF Executive Director at meetings
GSK’s  April and November European Health Advisory Board 
(4) 2011 contribution received in 2010
EPF wishes to thank the following sponsors for their support in the form of unrestricted grants to EPF'S
events in 2011 :
Annual General Meeting
Eli Lilly € 20,000.00 2.5%
Hoffmann La Roche € 20,000.00 2.5%
Janssen Pharmaceutica € 20,000.00 2.5%
Regional Advocacy Seminar
Medtronic Foundation € 30,000.00 3.8%
SANOFI AVENTIS € 15,000.00 1.9%
Conference on Rights and Needs of Older Patients
AMGEN € 10,000.00 1.3%
GSK * € 30,000.00 3.8%
Novartis € 30,000.00 3.8%
Pfizer € 30,000.00 3.8%
* 2011 Contribution paid in 2010
EPF wishes to thank the European Commission for its support in 2011 
in relation to Epf's role in the following projects :
Respect * € 16,311.00 2.1%
Renewing Health * € 27,163.92 3.4%
Interquality  € 48,094.00 6.1%
Chain of Trust € 41,376.65 5.2%
E-Health Governance € 4,500.00 0.6%
* 2011 contribution to be received in 2012